Credit Suisse Group Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $93.00

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) had its target price raised by Credit Suisse Group from $90.00 to $93.00 in a report released on Wednesday morning, Marketbeat reports. They currently have a neutral rating on the biotechnology company’s stock.

A number of other brokerages also recently issued reports on SRPT. StockNews.com downgraded shares of Sarepta Therapeutics from a buy rating to a hold rating in a research report on Saturday, May 21st. The Goldman Sachs Group reduced their price objective on shares of Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating on the stock in a research report on Tuesday, May 24th. Cantor Fitzgerald reduced their price objective on shares of Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating on the stock in a research report on Friday, June 24th. Morgan Stanley dropped their target price on shares of Sarepta Therapeutics from $77.00 to $74.00 and set an equal weight rating on the stock in a report on Thursday, May 19th. Finally, Barclays boosted their target price on shares of Sarepta Therapeutics from $104.00 to $125.00 in a report on Wednesday. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $126.92.

Sarepta Therapeutics Stock Up 4.5 %

Shares of NASDAQ SRPT opened at $106.02 on Wednesday. The company has a quick ratio of 5.13, a current ratio of 4.53 and a debt-to-equity ratio of 1.52. Sarepta Therapeutics has a 52 week low of $61.28 and a 52 week high of $107.03. The firm’s fifty day moving average is $78.23 and its 200 day moving average is $76.58. The company has a market cap of $9.28 billion, a price-to-earnings ratio of -18.06 and a beta of 1.27.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last issued its earnings results on Wednesday, May 4th. The biotechnology company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.15. Sarepta Therapeutics had a negative net margin of 60.66% and a negative return on equity of 67.98%. The company had revenue of $210.83 million for the quarter, compared to the consensus estimate of $208.25 million. During the same period in the previous year, the firm earned ($2.10) earnings per share. The firm’s revenue for the quarter was up 43.5% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics will post -4.48 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Janney Montgomery Scott LLC lifted its stake in Sarepta Therapeutics by 23.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,414 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 638 shares during the period. Xponance Inc. lifted its stake in Sarepta Therapeutics by 9.0% during the 4th quarter. Xponance Inc. now owns 9,332 shares of the biotechnology company’s stock valued at $840,000 after acquiring an additional 772 shares during the period. Assenagon Asset Management S.A. lifted its stake in Sarepta Therapeutics by 5,571.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 218,517 shares of the biotechnology company’s stock valued at $19,677,000 after acquiring an additional 214,664 shares during the period. AGF Investments Inc. lifted its stake in Sarepta Therapeutics by 71.4% during the 4th quarter. AGF Investments Inc. now owns 4,114 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 1,714 shares during the period. Finally, Yarbrough Capital LLC bought a new position in Sarepta Therapeutics during the 4th quarter valued at about $227,000. Institutional investors own 81.43% of the company’s stock.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Featured Articles

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.